However, 15–20% of breast tumors lack ERα, HER2 and a clinically relevant biomarker of ERα signaling, progesterone receptor (PGR); this subtype is termed triple-negative breast cancer (TNBC) [1]. This evidence concerns the gene PGR and breast neoplasm.